Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543435 | 0.79 | GPR35 (0.41) | ADORA2AADORA2B | |
| SCHEMBL6480113 | 0.79 | EGLN1 (0.49) | EGLN1 | |
| SCHEMBL13229696 | 0.75 | MEN1 (0.40) | ADORA2AADORA2B | |
| SCHEMBL967199 | 0.73 | EGLN1 (0.56) | EGLN1FTOEGLN2BBOX1KDM4C | |
| SCHEMBL483292 | 0.71 | ALDH1A1 (0.47) | — | |
| SCHEMBL1219793 | 0.71 | KDM4E (0.42) | EGLN1EGLN3 | |
| SCHEMBL821521 | 0.71 | EGLN1 (0.48) | EGLN1FTOEGLN2KDM4CKDM5B | |
| Pumosetrag SCHEMBL1497800 | 0.68 | HTR3A (0.56) | — | |
| Pumosetrag SCHEMBL7287985 | 0.68 | HTR3A (0.56) | — | |
| Pumosetrag SCHEMBL1497797 | 0.68 | HTR3A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309256-A1 | Therapeutic Method | FIBROGEN, INC | 2014-10-16 | — | — | US | disclosed |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | FIBROGEN, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110275697-A1 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. | 2011-02-17 | — | — | US | disclosed |
| CN-101917996-A | Methods for reducing blood pressure | FIBROGEN INC | 2010-12-15 | — | — | CN | disclosed |
| EP-2250264-A2 | REGULATION OF CYCLIN D | Dana-Farber Cancer Institute, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-2222305-A1 | METHODS FOR REDUCING BLOOD PRESSURE | Fibrogen, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010024911-A1 | METHODS FOR INCREASING NEUROGENESIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009102469-A2 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009058403-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | EGLN1 238/4885FTO 4088/4885EGLN2 215/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | EGLN1 1148/4885FTO 4102/4885EGLN2 866/4885 |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | HMGCR, MB, PDE3A | EGLN1 1790/4885FTO 3686/4885EGLN2 284/4885 |
| US-20110275697-A1 | REGULATION OF CYCLIN D | EGLN2, EGLN1, EGLN3 | EGLN1 2/4885FTO 4043/4885EGLN2 1/4885 |
| US-20140309256-A1 | Therapeutic Method | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885FTO 1807/4885EGLN2 3/4885 |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | HMGCR, MB, PDE3A | EGLN1 1790/4885FTO 3686/4885EGLN2 284/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | EGLN1 501/4885FTO 3763/4885EGLN2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.